Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on email@example.com
EpiCast Report Acromegaly and Gigantism Epidemiology Forecast to 2023
Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). GH excess beginning in adulthood is known as acromegaly, whereas GH excess beginning during childhood is known as gigantism.
To Browse a Full Report with Toc: http://www.researchmoz.us/epicast-report-acromegaly-and-gigantism-epidemiology-forecast-to-2023-report.html
GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acromegaly in the 6MM from 25,354 diagnosed prevalent cases in 2013 to 26,884 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 0.60% in the forecast period. Similarly, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of gigantism in the 6MM from 591 diagnosed prevalent cases in 2013 to 621 diagnosed prevalent cases in 2023, at an AGR of 0.51% in the forecast period. The 6MM had an estimated 22,408 diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment in 2013, and the number of diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment is expected to increase to 23,765 by 2023, at an AGR of 0.61%.
- The Acromegaly and Gigantism EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for acromegaly and gigantism in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism, segmented by sex, age (in 15-year age groups beginning at 15 years and ending atlent Cases of Acromegaly and Gigantism with Macroadenomas 43
3.7.2 Diagnosed Prevalent Cases of...